Acasă › Leucemie acută bifinotipică › Oklahoma
Studii clinice pentru Leucemie acută bifinotipică în Oklahoma
5 studii pentru Leucemie acută bifinotipică caută participanți în Oklahoma.
Orașe în Oklahoma
Text oficial al studiului (în engleză)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- University of Oklahoma Health Sciences Center, Oklahoma City
În curs de recrutareFaza 2
365 Days · Toate sexele · Actualizat 25 sept. 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Oklahoma Health Sciences Center, Oklahoma City
- Saint Francis Children's Hospital, Tulsa
În curs de recrutareFaza 3
365 Days – 25 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Oklahoma Health Sciences Center, Oklahoma City
În curs de recrutareFaza 1/2
Până la vârsta de 22 · Toate sexele · Actualizat 25 aug. 2026 · NCT04726241Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Saint Francis Children's Hospital, Tulsa
În curs de recrutareFaza 2
Vârste de la 1 la 18 · Toate sexele · Actualizat 10 aug. 2026 · NCT06390319Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
- Saint Francis Children's Hospital, Tulsa
În curs de recrutareFaza 4
Vârste de la 1 la 18 · Toate sexele · Actualizat 14 iul. 2026 · NCT06289673Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.